Search

everythinglearnresearchcommunity

for

Search:↓

Adipose-derived stem cells are promising for regenerative medicine due to their accessibility, versatility, and low risk of immune rejection.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Alopecia areata involves unique activation of certain immune cells.

Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

Autoimmune reactions may cause both alopecia areata and HAM.

Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.

Examining Survivin levels may help understand premature greying of hair.

The model showed that immune system guardians and the cytokine interferon-γ are key in alopecia areata progression.

CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.

ILC1-like cells can cause alopecia areata by disrupting hair follicle immunity, suggesting a new treatment approach.

Alopecia areata is linked to reduced T cell function and auto-immunity.

ILC1-like cells may contribute to hair loss in alopecia areata.

Innate lymphoid cells type 1 may contribute to alopecia areata.

HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.

ILC1-like cells can cause alopecia areata by affecting hair follicles.

Langerhans cells are crucial for skin immunity and allergic reactions.

Cats likely have a reactive skin condition, while dogs may have a more complex, possibly cancerous one.

CD8+ T cells drive alopecia areata, while regulatory T cells are protective.

Relatives of lupus patients show signs of immune system activity but not full-blown lupus.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

Feline cutaneous lymphocytosis is likely reactive, while canine cutaneous lymphocytosis needs more study to understand its nature.

A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

The muscle damage was caused by T-cell large granular lymphocytic leukemia, not dermatomyositis.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

A mutation in the IKZF1 gene causes immune system overactivity, linked to autoimmune diseases like lupus.